"Hematologic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Descriptor ID |
D019337
|
MeSH Number(s) |
C04.588.448 C15.378.400
|
Concept/Terms |
Hematologic Neoplasms- Hematologic Neoplasms
- Hematologic Malignancy
- Neoplasms, Hematologic
- Hematologic Neoplasm
- Neoplasm, Hematologic
- Hematological Neoplasms
- Hematological Neoplasm
- Neoplasm, Hematological
- Neoplasms, Hematological
- Malignancies, Hematologic
- Malignancy, Hematologic
- Hematologic Malignancies
- Hematological Malignancies
- Hematological Malignancy
- Malignancies, Hematological
- Malignancy, Hematological
Hematopoietic Neoplasms- Hematopoietic Neoplasms
- Neoplasms, Hematopoietic
- Hematopoietic Neoplasm
- Neoplasm, Hematopoietic
- Hematopoietic Malignancies
- Hematopoietic Malignancy
- Malignancies, Hematopoietic
- Malignancy, Hematopoietic
|
Below are MeSH descriptors whose meaning is more general than "Hematologic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Hematologic Neoplasms".
This graph shows the total number of publications written about "Hematologic Neoplasms" by people in this website by year, and whether "Hematologic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 4 | 0 | 4 |
1997 | 6 | 0 | 6 |
1998 | 5 | 2 | 7 |
1999 | 7 | 2 | 9 |
2000 | 7 | 3 | 10 |
2001 | 2 | 1 | 3 |
2002 | 8 | 8 | 16 |
2003 | 15 | 4 | 19 |
2004 | 11 | 6 | 17 |
2005 | 18 | 4 | 22 |
2006 | 20 | 9 | 29 |
2007 | 14 | 2 | 16 |
2008 | 14 | 8 | 22 |
2009 | 8 | 6 | 14 |
2010 | 19 | 6 | 25 |
2011 | 20 | 6 | 26 |
2012 | 21 | 3 | 24 |
2013 | 21 | 3 | 24 |
2014 | 25 | 6 | 31 |
2015 | 46 | 7 | 53 |
2016 | 30 | 6 | 36 |
2017 | 31 | 8 | 39 |
2018 | 40 | 4 | 44 |
2019 | 41 | 8 | 49 |
2020 | 34 | 5 | 39 |
2021 | 38 | 5 | 43 |
2022 | 49 | 1 | 50 |
2023 | 33 | 0 | 33 |
2024 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hematologic Neoplasms" by people in Profiles.
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar 01; 5(2):106-113.
-
Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. Oncology (Williston Park). 2024 03 01; 38(3):104-106.
-
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399.
-
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 Feb; 30(2):338-341.
-
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab. Cancer Med. 2024 Feb; 13(3):e6997.
-
miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities. Cells. 2023 12 30; 13(1).
-
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e130-e137.
-
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024 Feb; 37(2):100397.
-
Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review. Blood Adv. 2023 11 14; 7(21):6466-6491.